InflamaSYN (Zyflamend) Research and Testimonials

Compiled by New Mark

The Following Comments Support the Use of InflamaSYN (Formerly called Zyflamend)


“As the Director of Columbia University’s Center for Holistic Urology, I have recommended that my patients take Zyflamend to promote normal prostate functioning. Zyflamend has shown great promise in our urology lab as a highly active herbal formulation, and it has properties that may uniquely promote normal cellular activity in the prostate.* My patients and I are pleased with the results obtained with Zyflamend, and I recommend it to doctors and patients alike.”
—Aaron E. Katz M.D.
Director, Columbia University’s Center for Holistic Urology

“As Medical Director of an integrative health center, I use Zyflamend in my practice to promote a healthy inflammation response.* I have observed great benefit in patients with a wide range of needs, and I encourage the integrative use of this broad-spectrum herbal formulation.”
—Roberta Lee, M.D.
Medical Director, Continuum Center for Health and Healing

“As a practitioner of Integrative Medicine, I am always looking to use natural and safe interventions whenever possible. Science is beginning to show that a healthy inflammation response is important to the immune and cardiovascular systems, mental health, and virtually every other indicator of quality of life and longevity. I’ve found Zyflamend by NewMark to be the perfect supplement for my patients whenever inflammation support is required.”*
—James P. Nicolai, M.D.
Medical Director Franciscan Center for Integrative Health

“As an adjunct to my therapy, I have recommended Zyflamend to hundreds of patients and found it helpful in promoting a healthy inflammation response.* Our profession and other doctors interested in integrative therapies should encourage the use of herbal inflammation modulation, which has been an important part of natural and traditional medical systems for thousands of years.”
—David Radford, D.C.

“Zyflamend is the safe herbal formulation I use in my practice to promote a healthy inflammation response.* It actually acts as a “silent partner” by creating referrals and has helped me build my practice and my patient satisfaction.”
—Randall Schwartz, D.C.
Integrative Therapies

“As a Chiropractor, my goal is to balance the spine and relieve nerve interference. To modulate inflammation, Zyflamend is my product of choice.* The positive response has been overwhelming. You know you have a great product when patients come back asking for more.”
—Dr. Mark Joseph, D.C.

“I am a physician and surgeon, specializing for over twenty-five years in gynecologic oncology, and am now practicing urogynecology in which I have integrated complementary medicine. I was also the principal investigator of a human clinical trial using a Zyflamend based protocol with women undergoing chemotherapy treatment for recurrent ovarian cancer. Using the FACIT quality of life index, we determined that the Zyflamend protocol significantly enhanced the quality of life of the patients in the trial, and on the basis of that trial and my clinical experience, I think Zyflamend holds great promise as an adjuvant therapy for cancer patients undergoing conventional treatment. I also recommend Zyflamend for my patients to support a healthy inflammation response.”*
—Earl Surwit, M.D. Tucson, AZ

“The majority of my patients can value a supplement that supports a healthy inflammation response. I use Zyflamend as part of my treatment plan and I have seen great results restoring normal, healthy function to the prostate, gastrointestinal tract, and musculoskeletal system.”*
—Dr. Eliot W. Edwards, N.D.
Center for Integrative Health and Healing, Delmar, NY

“As an integrative pharmacist with expertise in herbal preparations, I believe that “best practices” in modern medicine should include the use of well-studied and safe herbal formulations that promote health and the quality of life. One such excellent preparation is Zyflamend, with strongly documented ability to support healthy inflammatory processes.* My patients and I have enthusiastically embraced Zyflamend, and the herbs in that formula have been shown to also promote normal cardiovascular and joint function.* It is an important part of my integrative practice.”
—Dave Foreman, R.Ph., N.D.
Host of the Natural Pharmacist, author of the forthcoming The Herbal Pharmacist’s Guide to Natural Cancer Therapies

“It is our belief that a combination of plant-based products obtained through a unique extraction process may provide a product where multiple components interact synergistically at relatively low doses. We think that this is a strategy for control of inflammation that may be more appropriate and perhaps even safer compared to the single targeted high dose pharmaceutical agent.”
—Robert A. Newman, Ph.D
Professor of Medicine and Pharmacology
Director, Pharmaceutical Development Center

* These statements have not been evaluated by the Food and Drug Administration.

Published Zyflamend Research

NewMark’s Zyflamend® is the subject of ongoing research at some of the world’s most prestigious research institutions, including Columbia University, MD Anderson Cancer Center, and the Cleveland Clinic.

Zyflamend((R))-Mediated Inhibition of Human Prostate Cancer PC3 Cell Proliferation: Effects on 12-LOX and Rb Protein Phosphorylation.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2007 Feb;6(2):228-36. Epub 2007 Feb 25

The multiherb anti-inflammatory product Zyflamend was investigated for its antiproliferative effects on PC3 human prostate cancer cells and eicosanoid metabolism in this prostate cancer cell line. Zyflamend produced a concentration-dependent inhibition of cloned COX-1, COX-2, and 5-LOX enzyme activities, with inhibition of 5-HETE production being greater than that of PGE(2) formation. Applied to intact PC3 cells, Zyflamend was found to be most potent against 12-LOX, followed by 5-LOX and then COX activities. The concentration-dependent inhibition of PC3 cell proliferation was associated with a selective G(2)/M arrest of the cell cycle and induction of apoptosis, as evidenced by flow cytometric staining of PC3 cells with annexin V. Zyflamend also produced a concentration-dependent down-regulation of 5-LOX and 12-LOX expression. Determination of cell signal transduction proteins demonstrated that Zyflamend produced an increase in p21 phosphorylation but down-regulated phosphorylation of retinoblastoma (Rb) protein. The decrease in pRb protein was shown to be due to 12-LOX inhibition and a decline in 12-HETE levels in the cells. Replenishing 12-HETE in Zyflamend-treated cells overcame the ability of this multiple herb product to inhibit cell proliferation, and concordantly, 12-HETE blocked Zyflamend’s ability to down-regulate phosphorylation of Rb protein. We conclude that the effective control of human prostate cancer cell proliferation with Zyflamend is multi-mechanistic but, in part, involves regulation of aberrant tumor cell eicosanoid metabolism, especially on 5- and 12-LOX, as well as restoration of Rb tumor suppressor protein function through regulation of its phosphorylation status.

The role of Zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report.

Department of Urology, Columbia University, New York, New York, USA. 2007 Mar;6(1):74-6.

Department of Urology, Columbia University,
New York, New York, USA.
Correlation between dietary intake and occurrence of prostate cancer has gained significant support in recent years. Although a direct correlation has yet to be proven between inflammation and prostate cancer, chronic or recurrent inflammation has been hypothesized to be the major predisposing factor for this disease. The authors have been studying Zyflamend, a novel herbal antiinflammatory mixture, as a potential chemopreventive agent in a phase 1 trial for patients diagnosed with prostatic intraepithelial neoplasia. They report the results of the first patient who has completed the 18-month study in which 24 patients were assigned to a cohort and placed on successive herbal supplement regimen starting with Zyflamend alone.

Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression.

Department of Urology, Columbia University Medical Center, New York, NY 10032, USA. 2005;52(2):202-12

Cyclooxygenase (COX) inhibitors have suppressive effects on several types of cancer cells including prostate cancer. In this study, we considered the potential COX-inhibitory activity of a unique anti-inflammatory herbal preparation (Zyflamend; New Chapter, Inc., Brattleboro, VT) and analyzed its effects on the human prostate cancer cell line LNCaP. COX inhibitory activity of Zyflamend was determined by a spectrophotometric-based assay using purified ovine COX-1 and COX-2 enzymes. Effects of Zyflamend on LNCaP cell growth and apoptosis in vitro were assessed by cell counting, Western blot detection of poly ADP-ribose polymerase (PARP) cleavage, and measurement of caspase-3 activity in treated and control cell extracts. Western blotting techniques were conducted to determine the effects of this herbal preparation on the expression of the cell signaling proteins, p21, androgen receptor (AR), phospho-protein kinase C (pPKC)(alpha/beta), and phospho (p)Stat3. The phospohorylation status of several signal transduction phosphoproteins was profiled using a high-throughput phosphoprotein screening assay in treated cells and compared to controls. Zyflamend dramatically decreased COX-1 and COX-2 enzymatic activity. Elevated p21 expression coincided with attenuated cell growth following treatment of LNCaP cells with Zyflamend. PARP cleavage fragments were evident, and caspase-3 activity was upregulated over the control indicating the ability of Zyflamend to induce apoptosis of these cells. Androgen receptor expression levels declined by 40%, and decreases were observed in the active forms of Stat3 and PKC(alpha/beta) in Zyflamend-treated LNCaP cells. Zyflamend inhibited both COX-1 and COX-2 enzymatic activities, suppressed cell growth, and induced apoptosis in LNCaP cells. However, our data suggests that the effects are likely due to COX-independent mechanisms potentially involving enhanced expression of p21 and reduced expression of AR, pStat3, and pPKC(alpha/beta).

Zyflamend, a Polyherbal Preparation, Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis Through Down-Regulation of NF-kappa B Activation and NF-kappa B-Regulated Gene Products.

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2007;57(1):78-87.

Zyflamend, a polyherbal preparation, was designed based on constituents that exhibit antiproliferative, antiinflammatory, antioxidant, antiangiogenic, and apoptotic activities through a mechanism that is not well defined. Because the nuclear factor (NF)-kappa B has been shown to regulate proliferation, invasion, and metastasis of tumor cells, we postulated that Zyflamend modulates the activity of NF-kappa B. To test this hypothesis, we examined the effect of this preparation on NF-kappa B and NFkappa B-regulated gene products. We found that Zyflamend inhibited receptor activator of NF-kappa B ligand-induced osteoclastogenesis, suppressed tumor necrosis factor (TNF)-induced invasion, and potentiated the cytotoxicity induced by TNF and chemotherapeutic agents, all of which are known to require NF-kappa B activation. Zyflamend suppressed NF-kappa B activation induced by both TNF and cigarette smoke condensate. The expression of NF-kappa B-regulated gene products involved in antiapoptosis (inhibitor-ofapoptosis protein 1/2, Bcl-2, Bcl-x(L), FADD-like interleukin-1I(2) converting enzyme/caspase-8 inhibitory protein, TNF receptorassociated factor-1, and survivin) and angiogenesis (vascular endothelial growth factor, cyclooxygenase-2, intercellular adhesion molecule, and matrix metalloproteinase-9) was also down-regulated by Zyflamend. This correlated with potentiation of cell death induced by TNF and chemotherapeutic agents. Overall, our results indicate that Zyflamend suppresses osteoclastogenesis, inhibits invasion, and potentiates cytotoxicity through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products.

See New Mark InflamaSYN (Zyflamend)